RTP Mobile Logo
Oncology Today with Dr Neil Love: Novel and Emerging Strategies for Diffuse Large B-Cell Lymphoma (Audio Program)
Released March 2021

Featuring an interview with Dr Gilles Salles. (Audio Program)

CE Information and Faculty Disclosures

  • TARGET AUDIENCE
    This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of diffuse large B-cell lymphoma.

    LEARNING OBJECTIVES

    • Appraise available clinical data in the formation of evidence-based therapeutic approaches for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
    • Consider the FDA approval of polatuzumab vedotin in combination with bendamustine and rituximab for patients with R/R DLBCL after at least 2 prior therapies, and consider how this agent can be appropriately and safely integrated into clinical management algorithms.
    • Understand the biologic rationale for, FDA approval of and available clinical trial findings with selinexor for patients with R/R DLBCL after at least 2 prior therapies, to determine the applicability of this therapeutic strategy in clinical practice.
    • Review the mechanism of action of tafasitamab, and appreciate available research data documenting the efficacy and safety of this novel anti-CD19 antibody in combination with lenalidomide for patients with R/R DLBCL.
    • Appreciate available efficacy and safety data with approved and investigational CAR (chimeric antigen receptor) T-cell therapies for R/R DLBCL, and identify patients for whom this approach may be appropriate.
    • Assess ongoing clinical research evaluating other novel strategies for DLBCL, and counsel appropriate patients regarding the potential benefits of trial participation.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    CME credit is no longer available for this issue

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY
    Audio Program: This CME activity consists of an audio component.
    CME credit is no longer available for this issue

    Video Program: This CME activity consists of a video component.
    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and his spouse/partner) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Gilles Salles, MD, PhD
    Service Chief, Lymphoma Service
    Memorial Sloan Kettering Cancer Center
    New York, New York

    Advisory Committee: AbbVie Inc, Allogene Therapeutics, Autolus Therapeutics, BeiGene Ltd, Bristol-Myers Squibb Company, Celgene Corporation, Debiopharm Group, Genmab, Kite, A Gilead Company, Incyte Corporation, Janssen Biotech Inc, Miltenyi Biotec, MorphoSys, Novartis, Roche Laboratories Inc, VelosBio Inc; Consulting Agreements: Bristol-Myers Squibb Company, Celgene Corporation, Debiopharm Group, Genmab, Kite, A Gilead Company, Incyte Corporation, Miltenyi Biotec, MorphoSys, Novartis, Roche Laboratories Inc.

    EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seagen Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Genentech, a member of the Roche Group and Incyte Corporation.

    Release date: March 2021
    Expiration date: March 2022

Acknowledge and close

Watch video
(WIFI is recommended for best performance):